This invention relates to the field of
biotechnology, specifically to a biosynthetic method for the synthesis of
daidzein precursors and
daidzein based on
daidzein catalysis. This invention synthesizes daidzein precursors glyceollidinⅠ (GD1) or glyceollidinⅡ (GD2) by co-expressing the genes AtPAL2, GmCHS8, GmCHR5, GmCHI1B1, GmIFS1, GmHID and AtMYB60, which are involved in daidzein synthesis, along with downstream daidzein genes GmI2'H, GmIFR, GmVR, GmPTS1, GmD6aH and GmG4DT, or GmI2'H, GmIFR, GmVR, GmPTS1, GmD6aH and GmG2DT, in *
Nicotiana benthamiana* mediated by *
Agrobacterium*. Furthermore, it co-expresses any one or a combination of several of the daidzein synthase genes GmGS1a, GmGS1b, GmGS2a, GmGS2b, GmGS3 / 7, and GmGS3e. This invention utilizes the Benedictine platform, based on daidzein, a key precursor in the
biosynthesis of highly accumulated
isoflavones, to reconstruct the biosynthetic pathways of the direct precursors of daidzein, GD1 and GD2. It elucidates the daidzein biosynthetic pathway, paving the way for
heterologous daidzein
biosynthesis and laying a scientific theoretical and technological foundation for the large-scale industrial production and medicinal function research of antibacterial daidzein.